Moheb Nasr

2.5k total citations
30 papers, 898 citations indexed

About

Moheb Nasr is a scholar working on Cell Biology, Spectroscopy and Biomedical Engineering. According to data from OpenAlex, Moheb Nasr has authored 30 papers receiving a total of 898 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Cell Biology, 6 papers in Spectroscopy and 6 papers in Biomedical Engineering. Recurrent topics in Moheb Nasr's work include Proteoglycans and glycosaminoglycans research (7 papers), Analytical Chemistry and Chromatography (5 papers) and Glycosylation and Glycoproteins Research (4 papers). Moheb Nasr is often cited by papers focused on Proteoglycans and glycosaminoglycans research (7 papers), Analytical Chemistry and Chromatography (5 papers) and Glycosylation and Glycoproteins Research (4 papers). Moheb Nasr collaborates with scholars based in United States, United Kingdom and Switzerland. Moheb Nasr's co-authors include Markus Krumme, Lucinda F. Buhse, David A. Keire, Ali Al‐Hakim, Charles L. Cooney, Alastair J. Florence, Salvatore Mascia, Konstantin Konstantinov, Bernhardt L. Trout and Allan S. Myerson and has published in prestigious journals such as Nature Biotechnology, Analytical Chemistry and The Journal of Physical Chemistry.

In The Last Decade

Moheb Nasr

30 papers receiving 866 citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Moheb Nasr 326 229 167 127 116 30 898
Sau Lee 252 0.8× 133 0.6× 35 0.2× 94 0.7× 73 0.6× 32 965
Hengchang Zang 341 1.0× 247 1.1× 84 0.5× 64 0.5× 645 5.6× 131 1.4k
Gabriele Betz 217 0.7× 88 0.4× 38 0.2× 101 0.8× 216 1.9× 53 1.2k
Takashi Iida 475 1.5× 87 0.4× 41 0.2× 233 1.8× 49 0.4× 163 1.6k
Cristina Fernández 634 1.9× 92 0.4× 97 0.6× 56 0.4× 37 0.3× 46 1.2k
Michael J. Akers 627 1.9× 142 0.6× 16 0.1× 102 0.8× 56 0.5× 50 1.2k
Wen Tan 679 2.1× 184 0.8× 22 0.1× 125 1.0× 66 0.6× 73 1.3k
Xin Peng 682 2.1× 119 0.5× 29 0.2× 120 0.9× 64 0.6× 75 1.4k
David P. Myers 158 0.5× 83 0.4× 36 0.2× 308 2.4× 365 3.1× 27 740

Countries citing papers authored by Moheb Nasr

Since Specialization
Citations

This map shows the geographic impact of Moheb Nasr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Moheb Nasr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Moheb Nasr more than expected).

Fields of papers citing papers by Moheb Nasr

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Moheb Nasr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Moheb Nasr. The network helps show where Moheb Nasr may publish in the future.

Co-authorship network of co-authors of Moheb Nasr

This figure shows the co-authorship network connecting the top 25 collaborators of Moheb Nasr. A scholar is included among the top collaborators of Moheb Nasr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Moheb Nasr. Moheb Nasr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Srai, Jagjit Singh, Massimo Bresciani, Charles L. Cooney, et al.. (2024). Emerging Applications and Regulatory Strategies for Advanced Medicines Manufacturing – Towards the Development of a Platform Approach. Journal of Pharmaceutical Sciences. 113(7). 1701–1710. 4 indexed citations
2.
Cooney, Charles L., Alastair J. Florence, Konstantin Konstantinov, et al.. (2019). Why We Need Continuous Pharmaceutical Manufacturing and How to Make It Happen. Journal of Pharmaceutical Sciences. 108(11). 3521–3523. 96 indexed citations
3.
Nasr, Moheb, Markus Krumme, Bernhardt L. Trout, et al.. (2017). Regulatory Perspectives on Continuous Pharmaceutical Manufacturing: Moving From Theory to Practice. Journal of Pharmaceutical Sciences. 106(11). 3199–3206. 103 indexed citations
4.
Chess, Edward K., K. B. JOHANSEN, Elaine Gray, et al.. (2016). The US regulatory and pharmacopeia response to the global heparin contamination crisis. Nature Biotechnology. 34(6). 625–630. 86 indexed citations
5.
Cooney, Charles L., et al.. (2015). Regulatory and Quality Considerations for Continuous Manufacturing May 20–21, 2014 Continuous Manufacturing Symposium. Journal of Pharmaceutical Sciences. 104(3). 803–812. 121 indexed citations
6.
Myerson, Allan S., et al.. (2014). Control Systems Engineering in Continuous Pharmaceutical Manufacturing May 20–21, 2014 Continuous Manufacturing Symposium. Journal of Pharmaceutical Sciences. 104(3). 832–839. 75 indexed citations
7.
Sommers, Cynthia D., Hongping Ye, Richard E. Kolinski, et al.. (2011). Characterization of currently marketed heparin products: analysis of molecular weight and heparinase-I digest patterns. Analytical and Bioanalytical Chemistry. 401(8). 2445–2454. 32 indexed citations
8.
Zang, Qingda, David A. Keire, Lucinda F. Buhse, et al.. (2011). Identification of heparin samples that contain impurities or contaminants by chemometric pattern recognition analysis of proton NMR spectral data. Analytical and Bioanalytical Chemistry. 401(3). 939–955. 19 indexed citations
9.
Zang, Qingda, David A. Keire, Richard D. Wood, et al.. (2010). Combining 1H NMR spectroscopy and chemometrics to identify heparin samples that may possess dermatan sulfate (DS) impurities or oversulfated chondroitin sulfate (OSCS) contaminants. Journal of Pharmaceutical and Biomedical Analysis. 54(5). 1020–1029. 17 indexed citations
10.
Zang, Qingda, David A. Keire, Richard D. Wood, et al.. (2010). Determination of galactosamine impurities in heparin samples by multivariate regression analysis of their 1H NMR spectra. Analytical and Bioanalytical Chemistry. 399(2). 635–649. 19 indexed citations
11.
Keire, David A., Hongping Ye, Michael L. Trehy, et al.. (2010). Characterization of currently marketed heparin products: key tests for quality assurance. Analytical and Bioanalytical Chemistry. 399(2). 581–591. 32 indexed citations
12.
Sadrieh, Nakissa, Lawrence X. Yu, William H. Doub, et al.. (2005). Stability, Dose Uniformity, and Palatability of Three Counterterrorism Drugs—Human Subject and Electronic Tongue Studies. Pharmaceutical Research. 22(10). 1747–1756. 41 indexed citations
13.
Jasper, John P., Benjamin J. Westenberger, John Spencer, Lucinda F. Buhse, & Moheb Nasr. (2004). Stable isotopic characterization of active pharmaceutical ingredients. Journal of Pharmaceutical and Biomedical Analysis. 35(1). 21–30. 42 indexed citations
14.
Bansal, Surendra K., et al.. (2004). Qualification of analytical instruments for use in the pharmaceutical industry: A scientific approach. AAPS PharmSciTech. 5(1). 151–158. 28 indexed citations
15.
Layloff, Thomas, Moheb Nasr, R. W. Baldwin, et al.. (2000). The FDA regulatory methods validation program for new and abbreviated new drug applications. 24(1). 30–42. 4 indexed citations
16.
Purdie, Neil, et al.. (1999). Algorithms for Validating Chiral Properties of Insulins. Analytical Chemistry. 71(16). 3341–3346. 2 indexed citations
17.
18.
Nasr, Moheb, et al.. (1997). High Performance Liquid Chromatographic Analysis of Erythromycin and Related Impurities in Pharmaceutical Formulations. Journal of Liquid Chromatography & Related Technologies. 20(4). 553–565. 9 indexed citations
19.
Nasr, Moheb, et al.. (1995). Loading Effect on Particle Size Measurements by Inertial Sampling of Albuterol Metered Dose Inhalers. Pharmaceutical Research. 12(11). 1677–1681. 10 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sau Lee Breakdown of academic impact, for papers by Hengchang Zang Breakdown of academic impact, for papers by Gabriele Betz Breakdown of academic impact, for papers by Takashi Iida Breakdown of academic impact, for papers by Cristina Fernández Breakdown of academic impact, for papers by Michael J. Akers Breakdown of academic impact, for papers by Wen Tan Breakdown of academic impact, for papers by Xin Peng Breakdown of academic impact, for papers by David P. Myers
Rankless by CCL
2026